Clinical efficacy of percutaneous endoscopic posterior lumbar interbody fusion and modified posterior lumbar interbody fusion in the treatment of lumbar degenerative disease

Zhengping Liu,Siyu Wang,Tao Li,Si Chen,Ying Li,Wei Xie,Jin Tang
DOI: https://doi.org/10.1186/s13018-024-04544-y
IF: 2.6
2024-01-19
Journal of Orthopaedic Surgery and Research
Abstract:To compare the early clinical efficacy of percutaneous endoscopic posterior lumbar interbody fusion (PE-PLIF) and modified posterior lumbar interbody fusion (MPLIF) in the treatment of lumbar degenerative disease (LDD).
orthopedics
What problem does this paper attempt to address?
This paper mainly discusses two surgical methods for treating degenerative lumbar diseases: percutaneous endoscopic transforaminal lumbar interbody fusion (PE-PLIF) and modified posterior lumbar interbody fusion (MPLIF), and their early clinical outcomes. The study retrospectively analyzed patient data from March 2019 to January 2022 who underwent these two surgeries. The study found that although the operation time of PE-PLIF was significantly longer than that of MPLIF, the intraoperative blood loss, postoperative hospital stay, and bed rest time were significantly less. In the early postoperative period, the VAS scores for leg pain and lower back pain and the Oswestry Disability Index (ODI) scores improved more significantly in the PE-PLIF group, and the JOA score at 3 days postoperatively was also higher. All patients showed interbody fusion at 6 months postoperatively. The conclusion is that both PE-PLIF and MPLIF are effective and safe for treating degenerative lumbar diseases in single-level segments, and PE-PLIF may be a promising alternative treatment. However, surgical selection should consider the operation time, recovery speed, and specific conditions of the patient.